Please ensure Javascript is enabled for purposes of website accessibility

Why Rite Aid Stock Is Climbing This Week

By Jeremy Bowman - Jul 22, 2021 at 4:40PM

Key Points

  • The stock gained on an apparent short squeeze.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the drugstore chain gained on what looked like a short squeeze.

What happened

Shares of Rite Aid (RAD 12.08%) were gaining this week with the pharmacy stock up 9.7% through Thursday. There was no major news out on the drugstore chain, but the stock did seem to benefit from a short squeeze as shares spiked early in the week, even on Monday when stocks broadly pulled back.

The exterior of a Rite Aid store

Image source: Rite Aid.

So what

As the influence of traders on forums like Reddit's WallStreetBets has grown, it's not uncommon to see stocks with high short interest move higher with little explanation. AMC Entertainment Holdings and GameStop are the best-known examples of this phenomenon, but dozens of other stocks have benefited from brief, unexplained surges as well.

As a well-known brand and one with 22% of its shares sold short, the company fits the bill of stocks that would get attention from WallStreetBets, and at least a few traders on the discussion board have pushed for a short squeeze on Rite Aid.

The stock jumped 6.8% on Monday on higher-than-normal volume even as the S&P 500 fell 1.6%. On Tuesday, Rite Aid gained another 6.3% on high volume before giving back some of those gains on Thursday.

In the pharmacy industry this week, Johnson & Johnson and three major drug distributors agreed to a $26 billion settlement to remove them from liability in the opioid crisis, and the prior week, Rite Aid and its pharmacy peers agreed to a $26 million settlement in an opioid lawsuit from two New York State counties, which could portend similar deals in the future.

Now what

Rite Aid has historically lagged behind the two leading pharmacy chains, CVS and Walgreens Boots Alliance, and has suffered under a heavy debt burden, which was $3 billion as of its most recent earnings report. Without the related interest expense of $200 million a year, the company would be profitable, but the debt burden has been a nagging impediment in its turnaround attempts.

In its first-quarter earnings report in June, the stock fell when management forecast an adjusted loss for the year, while analysts had expected a profit. The good news there is that if the company can top the subdued guidance it gave, the stock should move higher from here.

Jeremy Bowman owns shares of CVS Health. The Motley Fool recommends CVS Health and Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$10.58 (12.08%) $1.14
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$167.14 (-2.07%) $-3.53
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$104.25 (0.19%) $0.20
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$40.07 (0.43%) $0.17
GameStop Corp. Stock Quote
GameStop Corp.
GME
$39.45 (-2.67%) $-1.08
AMC Entertainment Holdings, Inc. Stock Quote
AMC Entertainment Holdings, Inc.
AMC
$25.46 (7.56%) $1.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.